PRALATREXATE
Pralatrexate is a chemotherapy medication classified as an antimetabolite and folate analog. It works by inhibiting the enzyme dihydrofolate reductase, which is essential for DNA synthesis, thereby slowing or stopping the growth of cancer cells. It is primarily used for the treatment of certain types of lymphoma.- Relapsed or refractory peripheral T-cell lymphoma (PTCL) in adults. - May be used in patients who have not responded to other therapies or whose disease has returned.
- Typically administered as an intravenous infusion. - Common regimen: 30 mg/m² once weekly for 6 weeks in 7-week cycles. - Dose adjustments may be required based on renal or hepatic function and patient tolerance.
- Known hypersensitivity to Pralatrexate or any of its components. - Pregnancy and breastfeeding (unless benefits outweigh risks). - Severe bone marrow suppression or active infections.
- Monitor blood counts regularly due to risk of myelosuppression. - Supplementation with folic acid and vitamin B12 is recommended to reduce toxicity. - Monitor liver and kidney function during treatment. - Avoid live vaccines during therapy.
Common: - Fatigue, nausea, vomiting - Mucositis (mouth sores) - Low blood counts (anemia, neutropenia, thrombocytopenia) Serious: - Severe infections due to immunosuppression - Liver toxicity - Pulmonary toxicity
- Concomitant use with other folate antagonists may increase toxicity. - Avoid combination with nephrotoxic drugs without close monitoring. - Live vaccines may be less effective or unsafe during treatment.
